FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type.

Christy Osgood,Flora Mulkey,Pallavi Shruti Mishra-Kalyani,Steven Lemery,Ashley Flynn Ward,Patricia Keegan,Rajeshwari Sridhara,Marc Robert Theoret,Richard Pazdur

FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type.

2019

Christy Osgood
Flora Mulkey
Pallavi Shruti Mishra-Kalyani
Steven Lemery
Ashley Flynn Ward
Patricia Keegan
Rajeshwari Sridhara
Marc Robert Theoret
Richard Pazdur

9508Background: Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 may not capture the full spectrum of benefit that patients with melanoma derive from targeted kinase inhibitors (TKI) or i...

Keywords:

Melanoma
Oncology
Randomized controlled trial
Pathology
Internal medicine
Medicine
in patient
metastatic melanoma
Response Evaluation Criteria in Solid Tumors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations